Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16099302 | 0.83 | TSHR (0.36) | KDM4EKMT2AMAPTSPRUSP2 | |
| SCHEMBL2246611 | 0.82 | KDM4E (0.42) | KDM4EKMT2AMAPTUSP2CNR1 | |
| Hydrochloric Acid SCHEMBL2593006 | 0.80 | KDM4E (0.41) | KDM4EKMT2AMAPTUSP2CNR1 | |
| SCHEMBL17243553 | 0.78 | L3MBTL1 (0.40) | KDM4EKMT2AMAPTSPRUSP2 | |
| Hydrochloric Acid SCHEMBL477643 | 0.76 | KMT2A (0.39) | KDM4EKMT2AMAPTTRPV4USP2 | |
| SCHEMBL16967062 | 0.76 | CNR1 (0.33) | KDM4ESPRCNR1CNR2ALDH1A1 | |
| SCHEMBL14243248 | 0.76 | KDM4E (0.44) | KDM4EKMT2AMAPTCNR1CNR2 | |
| SCHEMBL190917 | 0.75 | L3MBTL1 (0.45) | KDM4EKMT2AMAPTUSP2ALDH1A1 | |
| SCHEMBL17556147 | 0.75 | KDM4E (0.43) | KDM4EKMT2AMAPTUSP2ALDH1A1 | |
| SCHEMBL28894701 | 0.75 | KMT2A (0.44) | KDM4EKMT2AMAPTUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342089-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2017-11-30 | — | — | US | disclosed |
| US-9777018-B2 | Compounds as modulators of GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| EP-2718279-B1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2016-08-10 | — | — | EP | disclosed |
| US-20150361092-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2015-12-17 | — | — | US | disclosed |
| US-9181214-B2 | Bicyclic compounds as modulators of GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2015-11-10 | — | — | US | disclosed |
| WO-2012170867-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2012-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361092-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | GPR119, GPR39, GPBAR1 | KDM4E 3784/4885KMT2A 4075/4885MAPT 3977/4885 |
| US-20170342089-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | GPR119, GPR39, GPBAR1 | KDM4E 3784/4885KMT2A 4075/4885MAPT 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.